InvestorsHub Logo

massulo52

03/27/19 6:13 PM

#183675 RE: dukesking #183669

Put it this way, IMO most DM2 pts have weight problems and have higher trig levels, so most of them will be given or have the opportunity to be on V. Im sure Mr Cardio will agree.....

Cardiologymd

03/27/19 6:16 PM

#183676 RE: dukesking #183669

The market size is infinite. Millions of patients throughout the world. Sorry I cannot narrow it down but it will be huge like no other drug.

It would be bad if they sell themselves to BP for peanuts.

circuitcity

03/27/19 6:22 PM

#183681 RE: dukesking #183669

My 2cents. Somebody mentioned diabetic population in US is 30M. 10% penetration will be 3M, which translate to 4.5B annual rev per Dancing.

Put this in perspective with Statin add-on, which is primary target population for V and has 40M in US. But they are on only half time, so translate to 20M per HDG. So this diabetic SOC just snapped another equivalent market as stain add-on for V.